MilliporeSigma Expands HPAPI and ADC Mfg. Capabilities

MilliporeSigma is investing $65 million to expand its HPAPI and ADC manufacturing capabilities and capacity at its facility near Madison, WI. The investment will allow large-scale manufacturing of increasingly potent compounds that have the potential to treat cancer. Completion is expected by mid-2022 and should add approximately 50 full-time jobs starting in 2021.

The new 70,000-square-foot commercial building will be one of the largest dedicated HPAPI manufacturing facilities specifically designed to handle single-digit nanogram occupational exposure limit materials. The facility will incorporate containment areas to produce next-generation linker and payload materials for ADCs. The project is an addition to the company's Madison campus, which was the first commercial ADC facility in North America designed to handle highly active materials. It will join MilliporeSigma's campus in St. Louis, MO, which specializes in ADC bio-conjugation, active pharmaceutical ingredients, excipient and adjuvants manufacturing.

ADCs are an emerging class of medicines designed for high-specificity targeting and destruction of cancer cells, while preserving healthy cells. There are now only nine ADCs approved globally. However, the ADC industry is delivering strong growth and is expected to reach $15 billion by 2030.

While ADCs can provide many benefits compared with other therapeutic options, they also present a unique set of complex challenges, necessitating stringent containment infrastructure, requiring expertise in a number of different technologies for small and large molecules, as well as analytical capabilities. Due to these challenges, a majority ADC projects are outsourced to contract development and manufacturing organizations.